Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy (MESOIMMUNE)

Primary Outcome Measures

1. Disease control [ Time Frame: 12 weeks ]
   Disease control rate at 12 weeks

Secondary Outcome Measures

1. Survival with anti-PD1/PDL1 immunotherapy [ Time Frame: 12 weeks ]
   Overall survival from treatment with anti-PD1/PDL1 immunotherapy
2. Duration of treatment [ Time Frame: 12 weeks ]
   Duration of treatment with PD1/PDL1 immunotherapy
3. Survival [ Time Frame: 12 weeks ]
   Overall survival from the start of the first treatment
4. Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by previous immunotherapy [ Time Frame: 12 weeks ]
   Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by following data: which immunotherapy, date of treatment beginning/end
5. Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by adverse event [ Time Frame: 12 weeks ]
   Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by following data: numbers of treatment related adverse events from CTCAE v4.0
6. Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by remarkable event [ Time Frame: 12 weeks ]
   Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by following data: date of best response, date of progression, date of death)
7. To identify factors predictive of treatment response by immunotherapy in responder patients [ Time Frame: 12 weeks ]
   Identify factors predictive of treatment response by immunotherapy in responder patients by collecting following data: Demographics data, treatment data, and blood test results and histological data
8. To identify factors predictive of the response of immunotherapy treatment of progressive patients [ Time Frame: 12 weeks ]
   Identify factors predictive of treatment response by immunotherapy of progressive by collecting following data: Demographics data, treatment data, and blood test results and histological data
9. To identify factors predictive of the response of immunotherapy treatment of all patients [ Time Frame: 12 weeks ]
   Identify factors predictive of treatment response by immunotherapy of all patients by collecting following data: Demographics data, treatment data, and blood test results and histological data
10. To identify factors predictive of the response of immunotherapy treatment according to follow-up treatment [ Time Frame: 12 weeks ]
    Identify factors predictive of treatment response by immunotherapy according to type of treatment after PD1/PDL1 immunotherapy

Inclusion Criteria

• Patient over 18 years of age,
• Diagnosis of malignant pleural mesothelioma affirmed by the anatomo-pathological analysis report of a histological sample of the tumour (re-read by MESOPATH).
• Patient who has received at least one injection of anti-PD1 or anti-PDL1 antibodies

Exclusion Criteria

• Explicit refusal by the patient to collect data